Bovine bone morphogenetic protein (bBMP) induces differentiation of mesenchymal-type cells into cartilage and bone. bBMP has an apparent Mr of 18,500 ± 500 and represents <0.001% of the wet weight of bone tissue. A Mr 34,000 protein resembling osteonectin is separated by extraction with Triton X-100. A Mr 24,000 protein and about half of a Mr 22,000 protein are disassociated from bBMP by precipitation in 1.5 M guanidine hydrochloride. Aggregates of bBMP and a Mr 14,000 protein are insoluble in aqueous media; the bBMP becomes soluble when the Mr 14,000 protein is disassociated in 6 M urea and removed from the solution by ultrafiltration. Three separate molecular species with apparent Mrs 18,500, 17,500, and 17,000 are eluted at 0.10, 0.15, and 0.20 M phosphate ion concentrations, respectively, from a hydroxy-apatite column. The Mr 18,500 protein has the amino acid composition of acidic polypeptide and includes four halfcystine residues; the pI is 4.9-5.1. The Mr 22,000 component is a chromoprotein resembling ferritin. The NH12-terminal amino acid sequence of the Mr 17,500 protein simulates histone H2B.
tration. Three separate molecular species with apparent Mrs 18,500, 17 ,500, and 17,000 are eluted at 0.10, 0.15, and 0.20 M phosphate ion concentrations, respectively, from a hydroxy-apatite column. The Mr 18,500 protein has the amino acid composition of acidic polypeptide and includes four halfcystine residues; the pI is 4.9-5.1. The Mr 22,000 component is a chromoprotein resembling ferritin. The NH12-terminal amino acid sequence of the Mr 17,500 protein simulates histone H2B.
The Mr 17,000 protein may possess calmodulin activity. Aggregates of the Mr 18,500 and other proteins induce formation of large deposits of bone; the Mr 18,500 protein alone is rapidly absorbed and induces formation of small deposits. None of the other proteins induces bone formation.
Under the influence of bone morphogenetic protein (BMP), perivascular mesenchymal-type cells (pericytes) differentiate into cartilage and woven bone. BMP is an acidic polypeptide (1, 2) embedded in a complex assortment of intra-and extracellular protein aggregates derived from dentin (3) , bone (4, 5) , and osteosarcoma tissues (6) (7) (8) (9) . We report here on the purification of BMP by means of a combination of differential precipitation, ultrafiltration, and hydroxyapatite chromatography.
MATERIALS AND METHODS
Ten-kilogram batches of 1-year-old steer long bones were obtained from an abattoir. After the epiphyseal ends were cut away with a band saw, the diaphyses were mechanically scraped clean of soft tissues and extensively washed in cold water solution of 3 mM NaN3. The washed bone was frozen in liquid N2, ground in a Wiley mill to a particle size of 1 mm3, defatted in chloroform/methanol (1:1), and again washed in 10 liters of cold water (step 1). The bone particles were demineralized in 0.6 M HCl at 4°C for 48 hr and again extensively rewashed in NaN3 solution (step 2). The demineralized washed bone particles were chemically extracted to remove soluble noncollagenous protein (i.e., sialoproteins, plasma proteins, y-carboxyglutamyl proteins, and phosphoproteins), simultaneously converting the collagen to insoluble bone matrix gelatin (step 3) by previously described procedures (10) . Ten kilograms of whole wet bone produced -'1.4 kg of freeze-dried insoluble bone matrix gelatin. The BMP was extracted from the insoluble bone matrix gelatin in an inorganic/organic solvent mixture of 0.5 M CaCl2 in 6 M urea at 28°C for 24 hr containing 10 mM N-ethylmaleimide (NEM) to protect BMP against endogenous degradative enzymes.
The undissolved matrix and other substances were removed by filtration through cheesecloth. The supernatant solution was decanted, dialyzed against 23 vol of deionized water at 4°C, and allowed to stand overnight in the cold while a precipitate formed. The precipitate was collected by centrifugation (Sorvall RC-5B refrigerated superspeed) at 40,000 x g for 20 min, washed in cold deionized water, lyophilized, and weighed (Table 1, step 4) .
Sixty grams of the fraction obtained by step 4 (Table 1 ) was redissolved in the original 0.5 M CaCl2/6 M urea solution and dialyzed against 11 vol of 0.25 M citrate buffer (pH 3.1) at 4°C. After 24 hr, a grayish-white precipitate was collected by centrifugation at 40,000 x g for 1 hr. The precipitate was extensively washed, defatted in chloroform/methanol (1:1), and evaporated to dryness (step 5) .
Twenty-two grams of the fraction obtained by step 5 (Table 1) was redissolved in 4 M guanidine hydrochloride (Gdn HCl) and diluted to 1.5 M Gdn HCl by dialysis at 28°C for 12 hr or until formation of a precipitate. The 1.5 M Gdn HCl-soluble fraction was dialyzed against water for 24 hr, until precipitation was complete. The water-insoluble precipitate was centrifuged, extensively washed in cold water, lyophilized, and weighed (step 6, Table 1 ). The 1.5 M Gdn HCl-insoluble fraction was centrifuged at 50,000 x g for 1 hr, washed in cold water, lyophilized, and weighed (step 7). The protein fraction obtained by step 7 was redissolved in 0.5 M CaCl2/6 M urea and dialyzed against 0.2% Triton X-100 in 0.10 M Tris HCl buffer solution (pH 7.2) containing 6 M urea for 24 hr at 28°C. The retentate was dialyzed exhaustively against deionized water at 4°C until precipitation was complete and then lyophilized (step 8). The Triton X-100-soluble proteins were also lyophilized and weighed (step 9).
The precipitate from step 8 was redissolved in 6 M urea and further purified by ultrafiltration (Amicon; pore size, Mr 10,000). When dialyzed against water, most of the retentate did not precipitate and the soluble portion was Iyophilized and collected for chromatographic fractionation.
Ultrafiltration. Two-liter batches of the CaCl2/urea-soluble proteins in 0.01 M phosphate buffer (pH 7.0) in 6 M urea were filtered through an H1P1O-8 hollow fiber cartridge (Amicon; Mr 10,000, approximate cutoff). The retentate was washed by passing an additional 6 liters of 6 M urea through the hollow fibers and was dialyzed against deionized water at Proc. NatL Acad. Sci USA 81 (1984) 4TC. The precipitate and supernatant were lyophilized separately. NaDodSO4/Polyacrylamide Slab Gel Electrophoresis. The above described protein fractions were solubilized by incubation for 24 hr in 0.06 M Tris HCl (pH 6.8) containing 2 M urea and 0.2% NaDodSO4. Five microliters (2.5 mg/ml) of each sample was applied to a 12.6% gel with a 3% stacking gel and was electrophoresed at 25 mA. The gels were stained with 0.25% Coomassie brilliant blue R-250 in methanol/acetic acid/H20 (5:1:5). The molecular weights were determined by using low molecular weight standards (Pharmacia), with a range of Mr 94,000-14,400.
Preparative Gel Electrophoresis. Electrophoresis also was performed with protein fractions applied to tube gels. Stained and unstained gel cylinders were electrophoresed in parallel and sliced to separate the individual bands. Selected slices were applied to fresh disc gels with 3% agarose and reelectrophoresed to verify the homogeneity of the protein samples. The individual protein constituents were eluted with 6 M urea, dialyzed against water, and lyophilized.
Preparative Flatbed Electrofocusing in a Granulated Gel. Two-hundred-milligram samples were dissolved in 95 ml of 4 M urea and added to 5 ml of ampholyte (Biolyte, Bio-Rad). After electrofocusing, each band was cut out of the gel separately with a spatula. Each of the gel samples was transferred to columns and eluted with 5 ml of 6 M urea in 0.5 M CaCl2 for a solvent. The eluate was collected in tubes and the pH was determined for each sample.
Hydroxyapatite Chromatography. Hydroxyapatite columns of Bio-Gel HTP (Bio-Rad) were prepared by adding 15 g of hydroxyapatite to 100 ml of 0.05 M phosphate buffer (pH 7.3) containing 6 M urea. After 10 min the solvent was decanted and the hydroxyapatite was resuspended in 100 ml to give a settled bed height of 9 cm (volume, -55 ml). The column was equilibrated with 100 ml of starting buffer, using a gravity flow rate of 0.6 ml/min. Samples'of 100 mg of the preparation obtained by step 8 were dissolved in 6 M urea, applied to the column, and separated into fractions.
Hydrophobic Column HPLC. Further purification of the protein fraction isolated by hydroxyapatite chromatography was accomplished by HPLC using a hydrophobic column (Ultrapore, reverse-phase Spherogel column, Beckman).
One-milligram samples were dissolved in 0.1% phosphoric acid/0.1 M sodium perchlorate/5% trifluoracetic acid. The solution was applied to the column and eluted with a gradient of (i) 0.1% H3PO4/0.1 M NaClO4 in water and (ii) 0.1% H3PO4/0.1 M NaClO4 in a mixture of acetonitrile/H20 (70:30), in 100 min with a flow rate of 1.0 ml/min.
Amino Acid Analysis. The individual proteins isolated by preparative gel electrophoresis were hydrolyzed at 110'C for 24 hr in 6 M HCl in evacuated sealed tubes. Analysis for tryptophan was performed after hydrolysis at 110'C for 24 hr in 2.5 M KOH/cystine, following performic acid oxidation; y-carboxyglutamic acid was determined by P. A. Price (11) . Amino acid analysis was performed on an amino acid analyzer (Beckman 119 C) equipped with a Spectra Physics 4000 data reduction system. Amino Acid Sequences. The Mr 18,500 and Mr 17,500 components, further purified by hydrophobic column chromatography, were analyzed in the gas/liquid phase protein sequenator (12) .
Bioassay. BMP activity was determined by implantation of isolated protein fractions and individual proteins in the hindquarter muscles of Swiss-Webster strain mice and skull trephine defects in monkeys, dogs, and rats. $Half-cystine determined as cysteic acid after performic acid oxidation.
RESULTS
'Plus possibly some y-carboxyglutamic acid residues and one hydroxyproline residue.
The Mr 18,000 ± 500 putative BMP had a blocked NH2-terminus. Mercaptoethanol Reduction. No significant measurable differences in the electrophoretic mobility of the three components with Mrs in the range of 17,000-18,000 were noted before and after mercaptoethanol reduction. Nevertheless, BMP activity was destroyed by mercaptoethanol reduction. Bioassay. When the Mr 18,500 ± 500 component was present, implants of protein fractions isolated by hydroxyapatite chromatography induced bone formation in the mouse hindquarter muscles (Fig. 3 Left and Right) and produced regeneration in trephine defects in rat and dog skulls (Fig. 4) . Im- plants of 10 mg or more of Mr 14,000, 17,500, 17,000, 22,000, or 34,000 proteins, alone or in various combinations, failed to induce bone formation. Association of the Mr 18,500 protein with the Mr 14,000 protein decreased solubility in vitro, increased resorption time in vivo, and improved both the incidence and yield of new bone from implants of as little as 1 mg. Implants of combinations of Mr 18,500 protein with Mr 34,000 protein or Mr 34,000 protein and Mr 17,500 protein did not improve and may even have suppressed the bone formation. Implants of seven parts of Mr 22,000 protein, two parts of Mr 18,500 ± 500 protein, and one part of Mr 14,000 protein weighing 3 mg induced formation of bone consistently and in quantities exceeding the space the mouse thigh could contain (Fig. 5) .
DISCUSSION
Due to the densely packed bone matrix structure, the relatively small quantity compared with other noncollagenous proteins, and an inclination to form hydrophobic aggregates, BMP is difficult to isolate and purify. The first evidence that isolation was possible came when BMP was released from bone matrix gelatin by digestion with gelatinase, separated from the digest by coprecipitation with calcium phosphate (14) , and proven to be a noncollagenous protein in nature. However, it was not until it was quantitatively extracted from bone matrix by means of a CaCl2/urea solvent mixture and the hydrophobic low molecular weight proteins were solubilized and disassociated from each other in 4 M Gdn HCl that BMP was isolated in significant quantities for detailed analysis (4, 5, 15 Preparative IEF indicates the pI of the Mr 18,500 molecule to be in the range of 4.9-5.1 but does not produce clean separation of bBMP from the Mr 17,500, 17,000, or 14,000 proteins. The Mr 17,500 histone H2B-like protein has no BMP activity. We have implanted 2 mg of histone H2B, prepared from Dunn osteosarcoma (6), a tissue with higher BMP activity than bone itself, and observed no BMP activity. Present evidence is against any protein other than the Mr 18,500 protein as inducing bone formation. Osteoinductive activity is extinguished from bone matrix by mercaptoethanol reduction (17) . This observation suggests that the BMP is a disulfide-bonded molecule. Special investigations are required to determine the number of disulfide bonds and the position with respect to one or the other end of the molecule.
The affinity and capacity of BMP for calcium binding has not yet been measured but preliminary experiments indicate each to be on the order of serum proteins. However, Ca2+ alterations in the solubility of low molecular weight proteins associated with BMP are important and could influence the delivery of BMP to target cells. Upon further characterization, the Mr 14,000 protein is designated as matrix Gla protein (MGP); through formation of a MGP-Ca2+-BMP aggregate, MGP could regulate local transfer of BMP from matrix to mesenchyme (13) . BMP also adsorbs to bone mineral and coprecipitates with calcium phosphate, but it is completely recovered by extraction of the mineral with 4 M Gdn HCl. A summary of physicochemical properties of BMP prepared from experiments previously and presently performed by our research group follows: (i) acidic polypeptide; (ii) apparent Mr = 18,000 ± 500 and pI = 5.0 + 0.2; (iii) binds to hydroxyapatite; (iv) no carbohydrate detected; (v) soluble in neutral salt solution at pH 7.2; (vi) degraded by acid alcohol solutions; alkali sensitive; (vii) insolubilized by forming aggregates with Mr 14,000 proteins; (viii) may contain one residue of hydroxyproline; (ix) insoluble in chloroform/ methanol, absolute alcohol, and acetone; (x) BMP Mr 14, 000 complex: insoluble in Triton X-100 (non-ionic detergent); insoluble in 0.6 M HCl; soluble in 6 M urea or 4 M Gdn HCl; soluble in 0.1% NaDodSO4; soluble in 0.02% M HCl; partially soluble in ethylene glycol; (xi) nuclease (RNase and DNase) resistant; (xii) trypsin and chymotrypsin labile; (xiii) resistant to: chondroitinases A, B, and C, amylase, neuraminidase, hyaluronidase, alkaline phosphatase, acid phosphatase, chymopapain, collagenase, tyrosinase, and thermolysin.
